Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Selection of Patients with Monoclonal Grammopathy of Undetermined Significance is Mandatory for a Reliable Use of lnterleukin-6 and Other Nonspecific Multiple Myeloma Serum Markers

Selection of Patients with Monoclonal Grammopathy of Undetermined Significance is Mandatory for a... Serum levels of various immunochémical markers of clinical interest, as interleukin-6 (IL-6), C-reactive protein (CRP) and β<sub>2</sub>-microglobulin (β<sub>2</sub>M), were measured in sera from 98 subjects affected with monoclonal gammopathy of undetermined significance (MGUS; 80% of which bearing cancer too) and from 39 patients with multiple myeloma (MM). In addition, the ratio between serum IgG/IgA amounts (GAR) was also calculated in monoclonal gammopathies of IgG type. Consistent with our previous investigations, we found that tumor presence significantly influenced the serum levels of the various markers (except GAR) in MGUS patients; in fact, only when comparing MGUS without tumor and MM patients, was a clear difference observed for all markers considered. The data presented discourage the use of IL-6, CRP and β<sub>2</sub>M as discriminant indices between MGUS and MM patients, unless a careful selection of MGUS subjects is performed. Further investigations on these potential markers are therefore needed for a more rational clinical application. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Karger

Selection of Patients with Monoclonal Grammopathy of Undetermined Significance is Mandatory for a Reliable Use of lnterleukin-6 and Other Nonspecific Multiple Myeloma Serum Markers

Loading next page...
 
/lp/karger/selection-of-patients-with-monoclonal-grammopathy-of-undetermined-9ygceMc36s

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 1994 S. Karger AG, Basel
ISSN
0001-5792
eISSN
1421-9662
DOI
10.1159/000204128
Publisher site
See Article on Publisher Site

Abstract

Serum levels of various immunochémical markers of clinical interest, as interleukin-6 (IL-6), C-reactive protein (CRP) and β<sub>2</sub>-microglobulin (β<sub>2</sub>M), were measured in sera from 98 subjects affected with monoclonal gammopathy of undetermined significance (MGUS; 80% of which bearing cancer too) and from 39 patients with multiple myeloma (MM). In addition, the ratio between serum IgG/IgA amounts (GAR) was also calculated in monoclonal gammopathies of IgG type. Consistent with our previous investigations, we found that tumor presence significantly influenced the serum levels of the various markers (except GAR) in MGUS patients; in fact, only when comparing MGUS without tumor and MM patients, was a clear difference observed for all markers considered. The data presented discourage the use of IL-6, CRP and β<sub>2</sub>M as discriminant indices between MGUS and MM patients, unless a careful selection of MGUS subjects is performed. Further investigations on these potential markers are therefore needed for a more rational clinical application.

Journal

Acta HaematologicaKarger

Published: Jan 1, 1994

Keywords: Interleukin-6; Monoclonal gammopathy of undetermined significance; Multiple myeloma Serum markers

There are no references for this article.